Cagrilintide
Also known as: NN9838
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Who's worth your money for Cagrilintide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 31 scored sellers
$1050 · 200mg · 99.7% purity
Best value after code
$1.98/mg effective with 10% code
$22.00 · 10mg
Most tested
10 independent COAs on file
$44.00 · 5mg · 99.9% purity
Average price
$11.80/mg
Sellers
52
45-day trend
-14.4%
45 of 52 sellers have a current price· 5 stale hidden· 9 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · just now
$5.25/mg -55.5% vs avg$1050
200mg
- 🇺🇸 Glacier Aminos99
✓ verified at source · 1h ago
$5.70/mg -51.7% vs avg$56.99
10mg
- 🇺🇸 Moglabs98
via Disclosed Labs · just now
$8.20/mg -30.5% vs avg$82.00
10mg
- 🇺🇸 BioLongevity Labs96
via Disclosed Labs · just now
$34.00/mg +188.1% vs avg$170
5mg
- 🇺🇸 Sunrise Bioresearch95
via Disclosed Labs · just now
$2.49/mg -78.9% vs avg$249
100mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · just now
$4.45/mg -62.3% vs avg$89.00
20mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · just now
$8.30/mg -29.7% vs avg$83.00
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$9.00/mg -23.8% vs avg$89.99
10mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 1h ago
$10.80/mg -8.5% vs avg$108
10mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · just now
$7.00/mg -40.7% vs avg$70.00
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Cagrilintide
Get one email when the market actually moves — no newsletter, no noise.
About Cagrilintide
CAS
1415456-99-3
Molecular formula
C194H312N54O59S2
Sequence
KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP
Typical dose range
0.3–4.5 mg once weekly subcutaneous (Phase 2); 2.4 mg/week maintenance in Phase 3 REDEFINE/REIMAGINE trials
Half-life
~159–195 hours (~7–8 days)
COAs for Cagrilintide
150 third-party tests across 36 vendors. Each card links to the full report.
For
Cagrilintide
by VoriLabs· batch CAGL-M2609-A
For
Cagrilintide
by Moglabs· batch CAG-X-003
For
Cagrilintide
by Sunrise Bioresearch· batch 6WSEGN4
For
Cagrilintide
by Artisan Aminos· batch AA-CAG10-049
For
Cagrilintide
by Peptide Plugs· batch 103-11-ZB
For
Cagrilintide
by Hydro Research Peptides· batch HR-2026-2608
For
Cagrilintide
by EZ Peptides· batch EZP-CAG1006162026-02
For
Cagrilintide
by Ion Peptide· batch CGL5-06172026
For
Cagrilintide 10
by EZ Peptides· batch EZP-CAG10061620226-02
For
Cagrilintide
by Ion Peptide· batch CGL10-06252026
For
Cagrilintide
by Ion Peptide· batch CGL5-06242026
For
Cagrilintide
by Optima Supply· batch OS-2026-2806
For
Cagrilintide
by Hydro Research Peptides· batch HR-2026-3852
For
Cagrilintide
by Peptide Supply Co.· batch CGL10 06032026
For
Cagrilintide
by Novaglo Research· batch 13060126CE
For
Cagrilintide
by Soma Peptides· batch CAX0052658
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide 5mg
by EZ Peptides· batch EZP-CAG05051520226-12
For
Cagrilintide
by Nox Amino· batch NA-CG0526-01
For
Cagrilintide
by Peptide Partners· batch SPL-3792
For
Cagrilintide
by NG Peptide· batch CG10-12
For
Cagrilintide
by NG Peptide· batch CG05-08
For
Cagrilintide
by Modern Research Peptides· batch RHKC6242
20 citations indexed for Cagrilintide
Study · 2026
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials
Background Overweight status, obesity, and diabetes represent significant socioeconomic burdens that require long-term management.
Study · 2026
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Background Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
review · 2026
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
rct · 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
rct · 2026
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.